Nuheara (ASX:NUH) - Stock Price, News & Analysis

NUH Stock Overview

A wearables technology company, engages in the development and commercialization of hearing technology and products as regulated medical devices in Australia, the United States, and internationally. More details

NUH fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Earnings have declined by 11.8% per year over past 5 years

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

Does not have meaningful revenue (A$2M)

+ 2 more risks

Nuheara Limited Competitors

BirdDog Technology

ASX:BDT

AU$10.5m

Zimi

ASX:ZMM

AU$4.9m

ASX:TZL

AU$17.8m

Ambertech

ASX:AMO

AU$15.5m

Price History & Performance

Summary of all time highs, changes and price drops for Nuheara
Historical stock prices
Current Share Price	AU$0.081
52 Week High	AU$0.21
52 Week Low	AU$0.07
Beta	1.87
11 Month Change	0%
3 Month Change	3.85%
1 Year Change	-42.14%
33 Year Change	-90.36%
5 Year Change	-94.53%
Change since IPO	-91.38%

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Oct 09

Recent updates

Shareholder Returns

	NUH	AU Tech	AU Market
7D	0%	1.5%	1.4%
1Y	-42.1%	16.7%	17.7%

Return vs Industry: NUH underperformed the Australian Tech industry which returned 17.8% over the past year.

Return vs Market: NUH underperformed the Australian Market which returned 9.6% over the past year.

Price Volatility

Is NUH's price volatile compared to industry and market?
NUH volatility
NUH Average Weekly Movement	n/a
Tech Industry Average Movement	6.3%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: NUH has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine NUH's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Justin Miller	www.nuheara.com

Nuheara Limited, a wearables technology company, engages in the development and commercialization of hearing technology and products as regulated medical devices in Australia, the United States, and internationally. The company offers IQbuds2 MAX, a hearing bud; IQstream TV for streaming stereo sound from the TV to IQbuds MAX earbuds; IQbuds2 MAX accessories; and Bluetooth transmitters. It sells its products through retail and direct-to-consumer online sales platform.

Nuheara Limited Fundamentals Summary

How do Nuheara's earnings and revenue compare to its market cap?
NUH fundamental statistics
Market cap	AU$21.76m
Earnings (TTM)	-AU$12.62m
Revenue (TTM)	AU$1.93m

11.3x

P/S Ratio

-1.7x

P/E Ratio

Is NUH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NUH income statement (TTM)
Revenue	AU$1.93m
Cost of Revenue	AU$2.88m
Gross Profit	-AU$951.47k
Other Expenses	AU$11.67m
Earnings	-AU$12.62m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.047
Gross Margin	-49.27%
Net Profit Margin	-653.33%
Debt/Equity Ratio	46.3%

How did NUH perform over the long term?

See historical performance and comparison

NUH Stock Overview

Risk Analysis

Nuheara Limited Competitors

ASX:BDT

AU$10.5m

ASX:ZMM

AU$4.9m

ASX:TZL

AU$17.8m

ASX:AMO

AU$15.5m

Price History & Performance

Recent News & Updates

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 1.850332 million.

Nuheara Limited Announces the Retirement of David Cannington as Non-Executive Director

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.929624 million.

New major risk - Shareholder dilution

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Full year 2023 earnings released: AU$0.084 loss per share (vs AU$0.16 loss in FY 2022)

Recent updates

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 1.850332 million.

Nuheara Limited Announces the Retirement of David Cannington as Non-Executive Director

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.929624 million.

New major risk - Shareholder dilution

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Full year 2023 earnings released: AU$0.084 loss per share (vs AU$0.16 loss in FY 2022)

Nuheara Limited, Annual General Meeting, Nov 22, 2023

New major risk - Financial position

Nuheara Limited Announces Appointment of Catherine Morgan as Head of Compliance, Regulatory and Legal

New minor risk - Share price stability

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 4.4 million.

First half 2023 earnings released: AU$0.048 loss per share (vs AU$0.065 loss in 1H 2022)

Insufficient new directors

Nuheara Announces Commercial Availability of HP Hearing PRO OTC Hearing Aid

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.025401 million.

Nuheara Limited Receives US FDA Approval and Launches HP Hearing PRO

Nuheara Limited to Report Q1, 2023 Results on Oct 31, 2022

Nuheara Limited Announces the Resignation of Jean-Marie Rudd as CFO

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.10 loss in FY 2021)

Nuheara Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.15 loss per share (vs AU$0.093 loss in FY 2021)

Nuheara Limited Welcomes US Food and Drug Administration's Final Ruling, Establishing A Regulatory Category for Over-The-Counter (Otc) Hearing Aids in the United States

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Nuheara Limited Announces Executive Changes

Nuheara Limited has filed an IPO in the amount of AUD 5 million.

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Nuheara Submits 510(k) for U.S. FDA Clearance

Nuheara Announces Executive Changes

Nuheara Limited Announces Successful Clinical Trial Self-Fitted Hearing Aids

Nuheara Limited to Report Q2, 2022 Results on Jan 31, 2022

Nuheara Clinical Trial and FDA 510(K) Pathway Update

We Think Nuheara (ASX:NUH) Needs To Drive Business Growth Carefully

Nuheara Limited Provides Update on Clinical Trial and Pathway to FDA 510(K) Approval

Is Nuheara (ASX:NUH) In A Good Position To Deliver On Growth Plans?

Full year 2021 earnings released: AU$0.005 loss per share (vs AU$0.011 loss in FY 2020)

Nuheara Limited Receives U.S. FDA Registration and Hearing Aid Device Listing

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in 1H 2020)

What Can We Make Of Nuheara's (ASX:NUH) CEO Compensation?

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 11.5 million.

Nuheara Limited announced that it expects to receive AUD 11.5 million in funding

Nuheara Limited Appoints Warwick Sauer as Director

Is Nuheara (ASX:NUH) Using Debt In A Risky Way?

Nuheara Receives $2 Million Phase II Works with HP Inc

Full year earnings released - AU$0.011 loss per share

Nuheara Limited announced that it has received funding

Shareholder Returns

Price Volatility

About the Company

Nuheara Limited Fundamentals Summary

11.3x

-1.7x

Earnings & Revenue